%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Johnson & Johnson(JNJ) Stock Analysis | Healthcare
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.What is Johnson & Johnson?
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
The brief on Johnson & Johnson
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
What is Johnson & Johnson?
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 617.01B, and a P/E ratio of 30.0x.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (55)Similar stocks to compare
A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 0 | 0 |
| 6-9months | 330,142 shares $7.4M | 0 |
| 9-12months | 0 | 0 |
Openbook research
Articles mentioning JNJ
- Read
Medtronic Grew 13.7%. An Extra Week Supplied Half of It
Medtronic's 13.7% organic quarter included about 670bp from a 53rd fiscal week. The underlying rate is near 7%, and that is still the story.
- Read
Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox
This AbbVie stock analysis breaks down Q2 2026 results, the Skyrizi and Rinvoq franchises that replaced Humira, margins, the dividend and key risks.
- Read
Trading 212 Dividend Tracker: Track Your Income
Learn how to export Trading 212 data as a CSV, track dividend income in a spreadsheet, and use the Trading 212 API to automate your dividend tracking workflow.
- Read
How to Research a Stock: A Step-by-Step Process - 2026
Learn the best way to research stocks with a clear, step-by-step investment research workflow — from defining your criteria to valuation and choosing the right stock research tools.
- Read
What Is a Financial Analytics Dashboard? A UK Guide
A financial analytics dashboard consolidates portfolio data, market metrics, and performance insights into one visual interface. This guide explains what these dashboards do, what features matter most, and which financial analytics dashboard tools are best suited to different types of investors.